may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
It’s an injectable biologic drug used to treat rheumatoid arthritis, Crohn’s disease and ulcerative colitis. Patients usually take it twice a month. A biosimilar is a lower-cost version of a biologic that is approved by the Food and Drug Administration after regulators determine that it is highly similar to the original product. It’s not the same as a generic drug, which is a copy of a chemical-based medicine that is easier - and cheaper - to make.
The pharmacy benefit manager Optum Rx says it will add biosimilars from Boehringer Ingelheim and Sandoz, a division of the drugmaker Novartis, to its standard national formulary, or list of covered drugs, starting July 1.
Italia Ultime Notizie, Italia Notizie
Similar News:Puoi anche leggere notizie simili a questa che abbiamo raccolto da altre fonti di notizie.
Cheaper competition for Humira is hitting the market, but savings will depend on your insurancePatients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July.
Leggi di più »